Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 4, 2012, Pages 469-474

  Awa, K ^a   Satoh, H ^a   Hori, S ^a   Sawada, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

drug drug interactions; ibuprofen; low dose aspirin; non steroidal anti inflammatory drugs; pharmacokinetic pharmacodynamic model

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN;

ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; LOW DRUG DOSE; PREDICTION; REPEATED DRUG DOSE; SIMULATION; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; TIME;

ASPIRIN; COMPUTER SIMULATION; CYCLOOXYGENASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; IBUPROFEN; JAPAN; MODELS, BIOLOGICAL; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TIME FACTORS;

EID: 84863492263     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01313.x     Document Type: Article

References (19)

1. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA,. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J, 1991; 5: 2304-2312. (Pubitemid 21892908)
2. Loll PJ, Picot D, Garavito RM,. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol, 1995; 2: 637-643.
3. Picot D, Loll PJ, Garavito RM,. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature, 1994; 367: 243-249. (Pubitemid 24051139)
4. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation, 1985; 72: 1177-1184. (Pubitemid 16126796)
5. Evans AM,. Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S (+)-ibuprofen. J Clin Pharmacol, 1996; 36: 7s-15s.
6. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med, 2001; 345: 1809-1817.
7. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N,. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol, 2008; 101: 1060-1063.
8. Gengo FM, Rubin L, Robson M, Rainka M, Gengo MF, Mager DE, Bates V,. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol, 2008; 48: 117-122. (Pubitemid 350292265)
9. Schuijt MP, Huntjens-Fleuren HW, de Metz M, Vollaard EJ,. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol, 2009; 157: 931-934.
10. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol, 2005; 45: 1295-1301. (Pubitemid 40523153)
11. Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE,. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet, 2008; 47: 129-137.
12. Benedek IH, Joshi AS, Pieniaszek HJ, King SY, Kornhauser DM,. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol, 1995; 35: 1181-1186. (Pubitemid 26020040)
13. Suri A, Grundy BL, Derendorf H,. Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. Int J Clin Pharmacol Ther, 1997; 35: 1-8. (Pubitemid 27056787)
14. Yamamoto K, Abe M, Katashima M, Yamada Y, Sawada Y, Iga T,. Pharmacodynamic analysis of antiplatelet effect of aspirin in the literature-modeling based on inhibition of cyclooxygenase in the platelet and the vessel wall endothelium. Jpn J Hosp Pharm, 1996; 22: 133-141.
15. Qayyum R, Becker DM, Yanek LR, Moy TF, Becker LC, Faraday N, Vaidya D,. Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol, 2008; 101: 1359-1363.
16. Galliard-Grigioni KS, Reinhart WH,. A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation. Eur J Pharmacol, 2009; 609: 96-99.
17. MacDonald TM, Wei L,. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet, 2003; 361: 573-574. (Pubitemid 36207477)
18. Curtis JP, Wang Y, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM,. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ, 2003; 327: 1322-1323. (Pubitemid 37510454)
19. Patel TN, Goldberg KC,. Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med, 2004; 164: 852-856. (Pubitemid 38520625)